UBS initiates coverage on SAB Biotherapeutics with a Buy rating and $7 PT.

miércoles, 7 de enero de 2026, 3:32 pm ET1 min de lectura
SABS--

UBS initiates coverage on SAB Biotherapeutics with a Buy rating and $7 PT.

UBS initiates coverage on SAB Biotherapeutics with a Buy rating and $7 PT.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios